151 related articles for article (PubMed ID: 15182430)
21. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
[TBL] [Abstract][Full Text] [Related]
22. DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.
Powe DG; Dhondalay GK; Lemetre C; Allen T; Habashy HO; Ellis IO; Rees R; Ball GR
PLoS One; 2014; 9(1):e84428. PubMed ID: 24392136
[TBL] [Abstract][Full Text] [Related]
23. Hormone receptor expression in invasive breast cancer among Korean women and comparison of 3 antiestrogen receptor antibodies: a multi-institutional retrospective study using tissue microarrays.
Bae YK; Gong G; Kang J; Lee A; Cho EY; Lee JS; Suh KS; Lee DW
Am J Surg Pathol; 2012 Dec; 36(12):1817-25. PubMed ID: 23154769
[TBL] [Abstract][Full Text] [Related]
24. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
Harvey JM; Clark GM; Osborne CK; Allred DC
J Clin Oncol; 1999 May; 17(5):1474-81. PubMed ID: 10334533
[TBL] [Abstract][Full Text] [Related]
25. Quantitative real-time RT-PCR analysis of eight novel estrogen-regulated genes in breast cancer.
Sorbello V; Fuso L; Sfiligoi C; Scafoglio C; Ponzone R; Biglia N; Weisz A; Sismondi P; De Bortoli M
Int J Biol Markers; 2003; 18(2):123-9. PubMed ID: 12841681
[TBL] [Abstract][Full Text] [Related]
26. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
28. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
Yamashita H; Takahashi S; Ito Y; Yamashita T; Ando Y; Toyama T; Sugiura H; Yoshimoto N; Kobayashi S; Fujii Y; Iwase H
Cancer Sci; 2009 Nov; 100(11):2028-33. PubMed ID: 19659610
[TBL] [Abstract][Full Text] [Related]
29. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
Wang Y; Gong X; Zhang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
[TBL] [Abstract][Full Text] [Related]
30. A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
Tan W; Luo W; Jia W; Liang G; Xie X; Zheng W; Song E; Su F; Gong C
Oncotarget; 2016 Dec; 7(52):87312-87322. PubMed ID: 27894097
[TBL] [Abstract][Full Text] [Related]
31. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha.
Kawai H; Li H; Avraham S; Jiang S; Avraham HK
Int J Cancer; 2003 Nov; 107(3):353-8. PubMed ID: 14506733
[TBL] [Abstract][Full Text] [Related]
33. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
34. Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor.
Damstrup L; Andersen J; Kufe DW; Hayes DF; Poulsen HS
Ann Oncol; 1992 Jan; 3(1):71-7. PubMed ID: 1606073
[TBL] [Abstract][Full Text] [Related]
35. The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast.
Paone JF; Abeloff MD; Ettinger DS; Arnold EA; Baker RR
Surg Gynecol Obstet; 1981 Jan; 152(1):70-4. PubMed ID: 7455895
[TBL] [Abstract][Full Text] [Related]
36. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
37. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
38. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
[TBL] [Abstract][Full Text] [Related]
39. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
40. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Györffy B; Lanczky A; Eklund AC; Denkert C; Budczies J; Li Q; Szallasi Z
Breast Cancer Res Treat; 2010 Oct; 123(3):725-31. PubMed ID: 20020197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
